|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.24 SEK | -6.49% |
|
-11.43% | -28.53% |
| 08/05 | Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 14/02 | Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sprint Bioscience AB (publ) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 10.88 million compared to SEK 0.014 million a year ago. Revenue was SEK 11.53 million compared to SEK 0.348 million a year ago.
Net loss was SEK 5.04 million compared to SEK 14.8 million a year ago. Basic loss per share from continuing operations was SEK 0.07 compared to SEK 0.3 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -28.53% | 8.09M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
SPRINT BIOSCIENCE AB 
